E-Mail
Irvine, Calif., Feb. 9, 2021 Monoclonal antibodies are showing promise for improving outcomes for COVID-19 patients, but when a hospital is already beyond capacity, administering them can be a challenge. As hospitalizations soared across California, clinicians with UCI Health created a system for delivering monoclonal antibodies that is keeping hospital beds available for patients with the greatest need. The hospital bed is one of the most valuable resources that we have, which has been stretched thin by the COVID-19 pandemic, said Dr. Daniel S. Chow, an assistant professor in residence in radiological sciences and co-director for the Center for Artificial Intelligence in Diagnostic Medicine as well as the project s co-principal investigator. Every effort to expand the number of beds available counts, and that includes being proactive about preventing hospitalizations.
Press release content from Business Wire. The AP news staff was not involved in its creation.
New Coalition Launches Bid for Cancer Patients Bill of Rights and Multiyear Cancer Care Is Different Platform
February 4, 2021 GMT
DUARTE, Calif. (BUSINESS WIRE) Feb 4, 2021
Today, as communities and organizations across the globe commemorate World Cancer Day, a coalition of organizations are announcing a new campaign called Cancer Care Is Different, spearheaded by City of Hope, a world-renowned National Cancer Institute-designated comprehensive cancer center, American Cancer Society Cancer Action Network, California Chronic Care Coalition and International Myeloma Foundation. The campaign’s goal is to raise awareness about the adverse impact for patients that restricted access to leading cancer treatment centers, where the most advanced, life-saving therapeutics are available, causes, particularly during the COVID-19 pandemic, and to urge passage and adoption of a Cancer Patients Bil
Ralph Brandenberger,
Ph.D., to senior vice president, technical operations. Brandenberger joined the Nkarta team in 2018 and oversees the company s cell therapy manufacturing operations.
> Asklepios Biopharmaceutical tapped
Tracy Dowling as general counsel starting Jan. 25. Dowling will help manage and advise on corporate governance, business development transactions, license agreements, employment law and more. Most recently, Dowling served as associate general counsel at Spark Therapeutics.
> Precision oncology specialist OncoDNA signed on
Bernard Courtieu as CEO. Courtieu previously joined IntegraGen as CEO in 2007.
Eduardo Bravo,
OncoDNA s interim CEO since July 2020, will remain a consultant to the company s board.
> Abingdon Health named
Melanie Ross as chief financial officer, effective immediately. Ross will also serve on the company s board. Most recently, she was group finance director at GVO-B1; prior to that, Ross was chief financial office
of
LEXINGTON, Ky. (Jan. 28, 2021) UK HealthCare, home to the University of Kentucky Markey Cancer Center, has officially been recognized as a System of Excellence for Hidden Scar breast cancer surgery, the highest level of Hidden Scar designation. UK HealthCare is the first and only hospital system in Kentucky to be certified as a Hidden Scar System of Excellence. This surgical option provides the women of Kentucky with a procedure that effectively treats breast cancer while optimizing cosmetic results.
The American Cancer Society estimates that 3,800 Kentucky women will be diagnosed with breast cancer this year. Of those women, most will need surgery as part of their treatment. Though surgical techniques over the decades have improved, traditional breast cancer surgeries still leave visible scars behind.
SAN ANTONIO and BOSTON - Study findings released Tuesday in the
Journal of the American Medical Association (JAMA) hold both good news and bad news about transient ischemic attacks (TIAs), which are harbingers of subsequent strokes.
Sudha Seshadri, MD, professor of neurology at The University of Texas Health Science Center at San Antonio and director of the university s Glenn Biggs Institute for Alzheimer s and Neurodegenerative Diseases, is senior author of the study and senior investigator of the Framingham Heart Study, from which the findings are derived. She said the extensive follow-up of Framingham participants over more than six decades enabled the study to present a more-complete picture of the risk of stroke to patients after a TIA.